AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 21 Sep - The Intimation for Analyst/Investor meeting to be held on September 28, 2026.
Source: Bse
GPT Healthcare Limited (GPTHEALTH)
Small CapPharma stocks · Small cap · NSE
GPT Healthcare Limited operates in Hospitals, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 04:45 am ISTDetails
Quote21 Oct, 04:45 am IST
Base fundamentals06 Oct 2026 · screener
Latest result03 Aug, 10:16 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
58NeutralSMA20 -4.3% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 30
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
GPTHEALTHD candles · FIT view+2.1%Latest close ₹139.12 on 2026-10-19
Bar
-2.7%
RSI
30
MACD hist
-1.03
52W pos
40%
2026-10-19O ₹142.94H ₹142.94L ₹138.42C ₹139.12Vol 77,204 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
GPTHEALTHNifty PharmaNifty 500
- GPTHEALTH
- -6.7%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -1.1 pp
Chart stats
19 Oct 2026- From 52W high
- -20.5%
- 52W range position
- 40%
- ATR (14)
- 3.8%
- Volume vs 20D
- 0.77x
- Avg traded value
- ₹1.3 Cr
- 20D price channel
- ₹138 - ₹170.9
₹175
₹115 - ₹175
₹5.3
Latest completed session
20-session average
23.5% annualized volatility
Research snapshot
What the evidence says now
Investable fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · UNDERVALUED70
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent90
Revenue +17.8% · PAT +62.5% YoY
Technical
Neutral58
Price trend and sector-relative-strength timing.
Valuation
Legacy model+40.8%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence76
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 90/100Rev +18% YoY · PAT +63% YoY · margin expansion · operating leverage
Filed 03 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹126 Cr | +17.8% | +0.0% |
| EBITDA | ₹24 Cr | +41.2% | +14.3% |
| Operating margin | 19.0% | +300 bps | -100 bps |
| PAT | ₹13 Cr | +62.5% | -13.3% |
| PAT margin | 10.3% | +284 bps | -255 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 29.50
- P/B
- —
- EV/EBITDA
- 15.03
- Market Cap
- 1227.00Cr
Profitability
- ROE
- 28.50%
- ROCE
- 23.70%
- ROA
- 13.00%
- Dividend Y
- 1.67%
Growth (CAGR)
- Revenue 5Y
- 26.08%
- EPS 5Y
- 95.40%
- Revenue 3Y
- 18.00%
- EPS 3Y
- 18.00%
Balance Sheet
- Debt/Equity
- 0.61
- Interest Coverage
- 6.73×
- Altman Z
- 6.78
- Book Value
- —
Cash Flow
- FCF Yield
- 4.97%
- FCF Positive Y
- 2/5
- OCF
- 66.00 Cr
- EPS TTM
- 5.22
Shareholding
- Promoter Hold
- 65.57%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 59%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 473+16.2% vs prev
Net Profit
₹ CrLatest: 42.0-16.0% vs prev
Return on Equity
%Latest: 15.6-22.6% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 30.
- Price below SMA200 (long-term downtrend) — short-term bounces likely countertrend.
- SMA20 falling (~4.5% over last month) — short-term momentum negative.
- RSI(14) at 30 — falling, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 21% off 52W high · 21% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
57
RS percentile
Stage 1 Base / Transition
1M return
-16.3%
3M return
-6.7%
6M return
+2.8%
1Y return
-7.9%
RS 1D
+1
RS 20D
-15
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is within 5.5% of the 30-week proxy.
- The 30-week proxy changed +2.4% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 96.87-0.12%
RS vs Nifty 50097
Valuation & peers
U-Score 70 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 70 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Top Setup
Fundamental score breakdown
U band · UNDERVALUEDValuation11/30
Growth21/25
Quality17/20
Balance Sheet9/15
Cash Flow7/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
70
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
70/100 · legacy band UNDERVALUED
Positive drivers
- FCF yield is supportive at 5.0%.
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 40.8%.
Main drags
- Valuation is weaker at 11/30; verify the latest quarterly trend.
- Balance sheet is weaker at 9/15; verify the latest quarterly trend.
- Cash flow is weaker at 7/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
29.5
PB
—
EV/EBITDA
15.0
ROE
28.5%
ROCE
23.7%
FCF Yield
5.0%
Debt/Equity
0.6
MoS
+40.8%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
70
Previous: 70
Legacy U-Score band
UNDERVALUED
Previous: UNDERVALUED
Margin of safety
+40.8%
Previous: +40.8%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
70
70
70
68
68
68
70
70
70
70
70
70
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
—
Growth-justified P/E
45.0
Growth-justified Value
₹234.9
+40.8% MoS
PEG
0.46
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
GKSL
Small
Gujarat Kidney And Super Speciality Limited
Healthcare Services
match 163
36
94.8
11.1%
-95%
WATCHLIST
SHALBY
Small
Shalby Limited
Healthcare Services
match 163
28
36.7
2.5%
-856%
OVERVALUED
UNIHEALTH
SME
Unihealth Hospitals Ltd.
Healthcare Services
match 159
62
34.9
21.5%
+31%
UNDERVALUED
DRAGARWQ
Small
Dr Agarwals Eye Hospital Limited
Healthcare Services
match 157
61
32.7
24.2%
+28%
UNDERVALUED
CHANDAN
SME
Chandan Healthcare Ltd.
Healthcare Services
match 156
58
22.2
19.8%
+50%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
GPT Healthcare Limited operates in Hospitals, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
76Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 81st percentile of the scored universe and 73rd percentile within Pharma. Main check: results consistency is weak at 53/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
45 docs text-extracted · 20 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
81st percentile
overall median 67 · Pharma: 73rd pctile, median 70 · Small: 83rd pctile, median 66
Evidence depth
Financial-only
45 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
65
acceptable · profit to cash conversion
Balance sheet
81
strong · leverage and solvency
Discipline
90
strong · capital discipline
Results
53
watch · quarterly consistency
Trust positives
- ▸Promoter holding is 65.6%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 4.7%.
- ▸ROCE is 23.7%.
Trust risks
- ▸2 latest quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching GPT Healthcare Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
Annual report
Announcement under Regulation 30 (LODR)-Newspaper Publication 10 Jul - The copies of News Paper publication post dispatch of Annual Report including AGM Notice.
Source: Bse
Annual report
Reg. 34 (1) Annual Report. 9 Jul
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 3 Jul - Copies of News Paper publication regarding information on 37th Annual General Meeting of the Company.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Aug - Copies of News Paper publication on UFR for Q1FY2027.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 5 Jun - GPT Healthcare to host virtual analyst/institutional investor meeting on June 11, 2026.
Source: Bse
Concall transcriptMay 2026
May 2026 · Transcript
Source: Bse
Investor presentationMay 2026
May 2026 · PPT
Source: Bse
Concall transcriptMay 2026
May 2026 · Transcript
Source: Bse
Investor presentationMay 2026
May 2026 · PPT
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.